Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2

Status

Terminated 10Recruiting 6Completed 6Withdrawn 4

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 2Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Gynecologic 1Endocrine 1Breast 1

Conditions

Unspecified Adult Solid Tumor 1Triple Negative Breast Neoplasms 1Solid Tumors 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Endometrial Neoplasms 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Interventional × TIC10 compound × Clear all
NCT03932643 2026-01-20

ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

University of Nebraska

Phase 1 Completed
20 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03034200 2024-11-26

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Case Comprehensive Cancer Center

Phase 2 Completed
30 enrolled 12 charts
EndocrineNET

Neuroendocrine Tumors

NCT03394027 2022-08-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
30 enrolled 15 charts
BreastGynecologic

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02609230 2021-06-04

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Fox Chase Cancer Center

Phase 1 Completed
33 enrolled
Plasma cell

Multiple Myeloma

NCT02250781 2019-05-22

Oral ONC201 in Treating Patients With Advanced Solid Tumors

Rutgers, The State University of New Jersey

Phase 1 Completed
58 enrolled
Other solid neoplasm

Solid Tumors

NCT02324621 2019-05-22

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

Rutgers, The State University of New Jersey

Phase 1 Completed
26 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡